LY146032: activity and resistance development in vitro

J Antimicrob Chemother. 1987 Oct;20(4):513-7. doi: 10.1093/jac/20.4.513.

Abstract

LY146032, a new lipopeptide antibiotic, was compared with vancomycin, teicoplanin, cefamandole and ciprofloxacin, against 107 clinical isolates comprising methicillin-susceptible and methicillin-resistant Staphylococcus spp., Streptococcus faecalis and Corynebacterium spp. All staphylococci were susceptible to all agents, except that some of the methicillin-resistant strains were resistant to cefamandole. Only LY146032 and ciprofloxacin were bactericidal to Str. faecalis. Development of resistance was studied by serial transfers of ten selected strains. A stable greater than or equal to eight-fold increase of the MIC over the breakpoint was found to develop to a variable extent against all agents tested. Simultaneous development of resistance to any of the other antibiotics was registered in 11/200 tests.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Corynebacterium / drug effects
  • Daptomycin
  • Drug Resistance, Microbial
  • Enterococcus faecalis / drug effects
  • Microbial Sensitivity Tests
  • Peptides / pharmacology
  • Staphylococcus / drug effects

Substances

  • Anti-Bacterial Agents
  • Peptides
  • Daptomycin